RASAGILINE - TRIMA

Maa: Israel

Kieli: englanti

Lähde: Ministry of Health

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
05-06-2023

Aktiivinen ainesosa:

RASAGILINE AS MESYLATE

Saatavilla:

TRIMA ISRAEL PHARMACEUTICAL PRODUCTS MAABAROT LTD

ATC-koodi:

N04BD02

Lääkemuoto:

TABLETS

Koostumus:

RASAGILINE AS MESYLATE 1 MG

Antoreitti:

PER OS

Prescription tyyppi:

Required

Valmistaja:

TRIMA ISRAEL PHARMACEUTICAL PRODUCTS MAABAROT LTD, ISRAEL

Terapeuttinen alue:

RASAGILINE

Käyttöaiheet:

Treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Valtuutus päivämäärä:

2021-02-28

Pakkausseloste

                                PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986
This medicine is dispensed with a doctor’s
prescription only.
RASAGILINE-TRIMA
TABLETS
ACTIVE INGREDIENT
Each tablet contains:
rasagiline (as mesylate) 1 mg
For the list of inactive ingredients in the preparation,
see section 6 – “Additional information”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START
USING THIS MEDICINE. This leaflet contains concise
information about this medicine. If you have any
further questions, consult your doctor or pharmacist.
This medicine has been prescribed to treat your
illness. Do not pass it on to others. It may harm
them, even if it seems to you that their medical
condition is similar to yours.
1. WHAT IS THIS MEDICINE INTENDED FOR?
For the treatment of Parkinson’s disease (PD) as
monotherapy or as adjunct therapy with levodopa.
THERAPEUTIC GROUP:
Selective monoamine oxidase type B inhibitors.
With Parkinson’s disease, there is damage to cells
that produce dopamine in the brain. Dopamine
is a chemical substance in the brain involved in
movement
control.
Rasagiline-Trima
helps
to
increase and sustain levels of dopamine in the
brain. . BEFORE USING THIS MEDICINE
DO NOT USE THIS MEDICINE IF:
You
are
sensitive
(allergic)
to
the
active
ingredient (rasagiline) or to any of the other
ingredients in the medicine (see section 6 –
“Additional information”).
You are suffering from severe liver insufficiency.
Do not use Rasagiline-Trima concomitantly with
the following medicines:
pethidine (a strong pain killer).
monoamine oxidase inhibitors (whether given
as medicines for depression, for Parkinson’s
disease, or for any other indication, including
natural
or
medicinal
preparations
given
without a doctor’s prescription, e.g., St. John’s
Wort for depression).
You must wait at least 14 days between stopping
taking Rasagiline-Trima and starting treatment with
monoamine oxidase inhibitors or with pethidine.
SPECIAL WARNINGS ABOUT USING THIS MEDICINE
BEFORE BEGINNING TREATMENT WITH RA
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste arabia 05-06-2023
Pakkausseloste Pakkausseloste heprea 05-06-2023

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia